Design Therapeutics (DSGN) Other Non-Current Assets (2022 - 2025)
Design Therapeutics (DSGN) posted quarterly Other Non-Current Assets of $427000.0 for Q1 2025, little changed year-over-year from $427000.0 in Q1 2024, and little changed on a QoQ basis from $427000.0 in Q4 2024.
Design Therapeutics (DSGN) Other Non-Current Assets (2022 - 2025) Analysis & Trends
Design Therapeutics has reported Other Non-Current Assets for 4 years, with the latest figure at $427000.0 in Q1 2025.
- Other Non-Current Assets for Q1 2025 came in at $427000.0, changed 0.0% year-over-year; the trailing twelve-month figure through Mar 2025 was $427000.0 (changed 0.0% YoY), and the FY2024 annual result was $427000.0, down 0.7% from the prior year.
- Other Non-Current Assets steadied at $427000.0 in Q1 2025, from $427000.0 in the prior quarter.
- Over five years, Other Non-Current Assets peaked at $474000.0 in Q2 2022 and troughed at $427000.0 in Q1 2024.
- A 4-year average of $441583.3 and a median of $433500.0 in 2023 frame the typical range for Other Non-Current Assets.
- The widest annual swing landed in 2023, when Other Non-Current Assets fell 6.33%; it then changed 0.0% in 2025.
- A 4-year view of Other Non-Current Assets shows it stood at $459000.0 in 2022, then slipped by 6.32% to $430000.0 in 2023, then declined by 0.7% to $427000.0 in 2024, then changed by 0.0% to $427000.0 in 2025.
- Per Business Quant data, the three most recent Other Non-Current Assets figures were $427000.0 in Q1 2025, $427000.0 in Q4 2024, and $427000.0 in Q3 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Other Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 1.25 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 2.31 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 124.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 42.45 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 109.58 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 18,237.65 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 62.96 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 65.13 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 104.44 Mn |
| 10 | Design Therapeutics | 928.06 Mn | 720.67 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2025 | 427,000.00 |
| Dec 31, 2024 | 427,000.00 |
| Sep 30, 2024 | 427,000.00 |
| Jun 30, 2024 | 429,000.00 |
| Mar 31, 2024 | 427,000.00 |
| Dec 31, 2023 | 430,000.00 |
| Sep 30, 2023 | 437,000.00 |
| Jun 30, 2023 | 444,000.00 |
| Mar 31, 2023 | 452,000.00 |
| Dec 31, 2022 | 459,000.00 |
| Sep 30, 2022 | 466,000.00 |
| Jun 30, 2022 | 474,000.00 |